Results 1 to 10 of about 37,722 (251)

Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods

Biomolecules, 2021
Antithrombin (AT) is a serine protease inhibitor, its activity is highly accelerated by heparin. Mutations at the heparin-binding region lead to functional defect, type II heparin-binding site (IIHBS) AT deficiency.
Reka Gindele, Gabor Balogh, Judit Kállai   +2 more
exaly   +3 more sources

Factors influencing antithrombin activity following supplementation in sepsis-associated disseminated intravascular coagulation [PDF]

Thrombosis Journal
Background Antithrombin, a key regulator of the coagulation cascade, is often decreased in patients with sepsis-associated disseminated intravascular coagulation (DIC).
Tomoki Tanigawa, Toshiaki Iba, Cheryl L. Maier, Ecaterina Scarlatescu, Yutaka Kondo, Hideo Wada, Jerrold H. Levy   +6 more
doaj   +2 more sources

Antithrombin in sepsis revisited [PDF]

Critical Care, 2005
As the pivotal phase III randomized controlled clinical trial on antithrombin concentrate in patients with severe sepsis did not show a beneficial effect of antithrombin treatment on 28-day mortality, the interest in the potential use of this treatment modality in sepsis has diminished.
Levi, Marcel
openaire   +5 more sources

Association of antithrombin with development of trauma-induced disseminated intravascular coagulation and outcomes

Frontiers in Immunology, 2022
IntroductionTrauma activates the innate immune system to modulate hemostasis and minimize the damage caused by physiological bodily responses, including the activation of coagulation.
Takeshi Wada, Atsushi Shiraishi, Satoshi Gando, Satoshi Gando, Daijiro Kabata, Kazuma Yamakawa, Seitaro Fujishima, Daizoh Saitoh, Shigeki Kushimoto, Hiroshi Ogura, Toshikazu Abe, Toshikazu Abe, Toshihiko Mayumi, Yasuhiro Otomo   +13 more
doaj   +1 more source

Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury

Frontiers in Immunology, 2022
Coagulopathy management is an important strategy for preventing secondary brain damage in patients with traumatic brain injury (TBI). Antithrombin (AT) is a natural anticoagulant that controls coagulation and inflammation pathways.
Masaki Takahashi, Takeshi Wada, Ryuta Nakae, Yu Fujiki, Takahiro Kanaya, Yasuhiro Takayama, Go Suzuki, Yasutaka Naoe, Shoji Yokobori   +8 more
doaj   +1 more source

Interactions of marine sulfated glycans with antithrombin and platelet factor 4

Frontiers in Molecular Biosciences, 2022
The molecular interactions of sulfated glycans, such as heparin, with antithrombin (AT) and platelet factor 4 (PF4) are essential for certain biological events such as anticoagulation and heparin induced thrombocytopenia (HIT).
Wenjing Zhang, Weihua Jin, Weihua Jin, Vitor H. Pomin, Fuming Zhang, Robert J. Linhardt, Robert J. Linhardt   +6 more
doaj   +1 more source

The antithrombin activity recovery after substitution therapy is associated with improved 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation

Thrombosis Journal, 2023
Background Disseminated intravascular coagulation (DIC) is a common and critical complication in sepsis. Antithrombin activity, which is considered a biomarker for disease severity, was measured in septic DIC treated with antithrombin concentrates in ...
Toshiaki Iba, Tomoki Tanigawa, Hideo Wada, Jerrold H. Levy   +3 more
doaj   +1 more source

The Interaction of Factor Xa and IXa with Non-Activated Antithrombin in Michaelis Complex: Insights from Enhanced-Sampling Molecular Dynamics Simulations

Biomolecules, 2023
The interaction between coagulation factors Xa and IXa and the activated state of their inhibitor, antithrombin (AT),have been investigated using X-ray diffraction studies. However, only mutagenesis data are available for non-activated AT. Our aim was to
Gábor Balogh, Zsuzsanna Bereczky
doaj   +1 more source

Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study

Turkish Journal of Hematology, 2021
Objective: The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients.
İlkay Anaklı, Perihan Ergin Özcan, Özlem Polat, Günseli Orhun, Gülçin Hilal Alay, Verda Tuna, Emre Çeliksoy, Mehmet Kılıç, Mutlu Mercan, Achmet Ali, Sevgi Beşışık, Figen Esen   +11 more
doaj   +1 more source

Case report: A case of new mutation in SERPINC1 leading to thrombotic microangiopathy

Frontiers in Genetics, 2023
Introduction: Hereditary antithrombin-III deficiency can significantly increase the risk for thrombosis, which is common in limb deep vein and pulmonary cases. However, thrombotic microangiopathy (TMA) caused by hereditary antithrombin deficiency is rare.
Bing Li, Xiaohui Zhang, Hailin Lv, Xiaoqing Yang, Yanxia Gao, Zhao Hu, Chengjun Ma   +6 more
doaj   +1 more source